MNPR

SEC filing MNPR Reports Positive Phase 2 ALXN1840 Data, Shows -0.37mg Daily Copper Balance Change, 50% Increase in Fecal Copper Output-to-Intake Ratio

13d ago

SEC filing MNPR Presents Phase 3 Neurologic Wilson Disease Data, ALXN1840 Shows 45% Improvement vs 32% SoC, Durable Benefit, Favorable Safety

43d ago

News Reynolds Consumer Products outlines flat 2026 adjusted EBITDA outlook as competitive pressures intensify

118d ago

News Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

153d ago

Scanner Unusual volume (z=3.5)

160d ago

Scanner Unusual volume (z=3.5)

162d ago

Scanner Unusual volume (z=3.5)

163d ago

Scanner Unusual volume (z=3.5)

164d ago